Real-world studies have aimed to compare the effects of 8- and 12-week ledipasvir/sofosbuvir regimens on sustained virological response (SVR) among HCV infection genotype-1 (HCV-1) treatment-naive patients. Nevertheless, real-world comparative effectiveness studies pose unique challenges, such as confounding by indication, that were not adequately addressed in prior studies. We thus aimed to address limitations in prior studies and compare overall- and subgroup-specific effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens among HCV-1 treatment-naive patients.
Methods
Patients eligible for our study were aged ≥18 years and initiated 8- or 12-week ledipasvir/sofosbuvir regimens for treatment-naive HCV-1 at an urban public hospital network. We excluded patients with HIV or cirrhosis. We used marginal structural models to estimate overall and subgroup-specific risk ratios (RRs) and 95% confidence limits (CL) comparing the effect of 8- and 12-week ledipasvir/sofosbuvir regimens on 12-week SVR.
Results
Our study population comprised 191 patients. Among both regimens, the majority were aged >50 years, non-Hispanic White and uninsured. The overall risk of SVR was comparable between the 8- and 12-week regimens (RR=1.01, 95% CL: 0.92, 1.11). The risk of SVR did not vary by race/ethnicity (non-Hispanic Black: RR=1.01, 95% CL: 0.84, 1.21; non-Hispanic White: RR=1.01, 95% CL: 0.89, 1.04).
Conclusions
Our real-world results suggest that 8- and 12-week ledipasvir/sofosbuvir have comparable effects on SVR among HCV-1 patients without cirrhosis or HIV. In addition, the comparable effectiveness of 8- and 12-week regimens among non-Hispanic Black individuals adds to the growing body of evidence that supports the removal of race-based treatment guidelines.
References
1.
QianX.J., ZhuY.Z., ZhaoP., QiZ.T.Entry inhibitors: new advances in HCV treatment.Emerg Microbes Infect2016; 5: e3.
2.
AfdhalN., ZeuzemS., KwoP.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med2014; 370: 1889–1898.
3.
KowdleyK.V., GordonS.C., ReddyK.R.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.N Engl J Med2014; 370: 1879–1888.
BackusL.I., BelperioP.S., ShahoumianT.A., LoomisT.P., MoleL.A.Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.Hepatology2016; 64: 405–414.
6.
BackusL.I., BelperioP.S., ShahoumianT.A., LoomisT.P., MoleL.A.Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.Antivir Ther2017; 22: 481–493.
7.
TerraultN.A., ZeuzemS., Di BisceglieA.M.Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response.Gastroenterology2016; 151: 1131–1140.e5.
8.
BuggischP., VermehrenJ., MaussS.Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.J Hepatol2017; 68: 663–671.
9.
JohnsonS.W., AmmiratiS.R., HartisC.E.Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.Int J Antimicrob Agents2017; 49: 778–781.
10.
LaiJ.B., WittM.A., PaulyM.P.Eight- or 12-week treatment of hepatitis C with ledipasvir/sofosbuvir: real-world experience in a large integrated health system.Drugs2017; 77: 313–318.
11.
NguyenM.H., TrinhH., DoS., NguyenT., NguyenP., HenryL.Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naive or experienced patients.Am J Gastroenterol2017; 112: 1824–1831.
12.
CurryM.P., TapperE.B., BaconB.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients.Aliment Pharmacol Ther2017; 46: 540–548.
13.
MarcusJ.L., HurleyL.B., ChamberlandS.No difference in effectiveness of 8 vs 12 weeks of ledipasvir and sofosbuvir for treatment of hepatitis C in Black patients.Clin Gastroenterol Hepatol2018; 16: 927–935.
14.
OjhaR.P., SteyerbergE.W.Real-world data on antiviral treatments for hepatitis C virus infections: can we define intention to treat or per protocol analyses?J Hepatol2018; 69: 551–553.
15.
MortonJ.B., McConeghyR., HeinrichK., GattoN.M., CaffreyA.R.Consensus of recommendations guiding comparative effectiveness research methods.Pharmacoepidemiol Drug Saf2016; 25: 1354–1360.
16.
ChahalH.S., MarseilleE.A., TiceJ.A.Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population.JAMA Intern Med2016; 176: 65–73.
17.
MorganJ.R., KimA.Y., NaggieS., LinasB.P.The effect of shorter treatment regimens for hepatitis C on population health and under fixed budgets.Open Forum Infect Dis2017; 5: ofx267.
18.
MathesT., PieperD.Study design classification of registry-based studies in systematic reviews.J Clin Epidemiol2018; 93: 84–87.
19.
CaseyJ.A., SchwartzB.S., StewartW.F., AdlerN.E.Using electronic health records for population health research: a review of methods and applications.Annu Rev Public Health2016; 37: 61–81.
20.
WestreichD., ColeS.R.Invited commentary: positivity in practice.Am J Epidemiol2010; 171: 674–677.
21.
YoshidaE.M., SulkowskiM.S., GaneE.J.Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.Hepatology2015; 61: 41–45.
22.
DanaeiG., Garcia RodriguezL.A., CanteroO.F., LoganR.W., HernanM.A.Electronic medical records can be used to emulate target trials of sustained treatment strategies.J Clin Epidemiol2018; 96: 12–22.
23.
HernánM.A., RobinsJ.M.Estimating causal effects from epidemiological data.J Epidemiol Community Health2006; 60: 578–586.
24.
ColeS.R., HernanM.A.Constructing inverse probability weights for marginal structural models.Am J Epidemiol2008; 168: 656–664.
25.
GreenlandS., PearlJ., RobinsJ.M.Causal diagrams for epidemiologic research.Epidemiology1999; 10: 37–48.
26.
PearlJ.Causality: models, reasoning, and inference.2 ed.Cambridge, England: Cambridge University Press2009.
27.
ZouG.A modified Poisson regression approach to prospective studies with binary data.Am J Epidemiol2004; 159: 702–706.
28.
AltmanD.G., BlandJ.M.Interaction revisited: the difference between two estimates.BMJ2003; 326: 219.
29.
BoscoJ.L., SillimanR.A., ThwinS.S.A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.J Clin Epidemiol2010; 63: 64–74.
VanderWeeleT.J., DingP.Sensitivity analysis in observational research: introducing the E-value.Ann Intern Med2017; 167: 268–274.
32.
DingP., VanderWeeleT.J.Sensitivity analysis without assumptions.Epidemiology2016; 27: 368–377.
33.
KowdleyK.V., SundaramV., JeonC.Y.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.Hepatology2017; 65: 1094–1103.
34.
ThompsonS.G.Why sources of heterogeneity in meta-analysis should be investigated.BMJ1994; 309: 1351–1355.
35.
LauJ., IoannidisJ.P., SchmidC.H.Summing up evidence: one answer is not always enough.Lancet1998; 351: 123–127.
36.
HernánM.A., Hernandez-DiazS., RobinsJ.M.A structural approach to selection bias.Epidemiology2004; 15: 615–625.
37.
SuF., GreenP.K., BerryK., IoannouG.N.The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.Hepatology2017; 65: 426–438.
38.
O'BrienT.R., Lang KuhsK.A., PfeifferR.M.Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.Open Forum Infect Dis2014; 1: ofu110.
39.
IoannouG.N., BesteL.A., ChangM.F.Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System.Gastroenterology2016; 151: 457–471.e5.
40.
WilderJ.M., JeffersL.J., RavendhranN.Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of Phase 3 data.Hepatology2016; 63: 437–444.
AltmanD.G., DeeksJ.J.Meta-analysis, Simpson's paradox, and the number needed to treat.BMC Med Res Methodol2002; 2: 3.
43.
BravataD.M., OlkinI.Simple pooling versus combining in meta-analysis.Eval Health Prof2001; 24: 218–230.
44.
JensenC.M., HolleL.M.Ledipasvir-sofosbuvir: a once-daily oral treatment option for chronic hepatitis C virus genotype 1 infection.Pharmacotherapy2016; 36: 562–574.
45.
O'BrienT.R., FeldJ.J., KottililS., PfeifferR.M.No scientific basis to restrict 8 weeks of treatment with ledipasvir/ sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/ml.Hepatology2016; 63: 28–30.
46.
BrookhartM.A., SturmerT., GlynnR.J., RassenJ., SchneeweissS.Confounding control in healthcare database research: challenges and potential approaches.Med Care2010; 48: S114–S120.
47.
RogalS.S., McCarthyR., ReidA.Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence.Dig Dis Sci2017; 62: 1933–1943.
48.
ZengQ.L., XuG.H., ZhangJ.Y.Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.J Hepatol2017; 66: 1123–1129.
